Improved targeting of pancreatic cancer: Experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy

Clinical Cancer Research

Volumn 10, Issue 10, 2004, Pages 3552-3561

  Cardillo, Thomas M ^a,c   Karacay, Habibe ^a   Goldenberg, David M ^a   Yeldell, Dion ^a   Chang, Chien Hsing ^b   Modrak, David E ^a   Sharkey, Robert M ^a   Gold, David V ^a  

^a GARDEN STATE CANCER CENTER   (United States)

^b IBC Pharmaceuticals Inc   (United States)

^c IMMUNOMEDICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMP 156; IMP 156 IN 111; IMP 192; IMP 192 TC 99M; INDIUM 111; MUCIN 1 ANTIBODY; PENTETATE INDIUM; PENTETATE INDIUM ANTIBODY; RITUXIMAB; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CHIMERA; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGING SYSTEM; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOIMMUNOASSAY; XENOGRAFT;

ANIMALS; ANTIBODIES; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CELL LINE, TUMOR; HAPTENS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PEPTIDES; RADIOIMMUNODETECTION; TIME FACTORS;

EID: 2542450935     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0340     Document Type: Article

References (84)

1. American Cancer Society, Cancer Facts and Figures, 2003. Atlanta: American Cancer Society, 2003. p. 16.
2. Ritts RE, DelVillano B, Go VLW, Herberman RB, Lug TL, Zurawski VR. Initial clinical evaluation of an immunoradiometric assay for CA19-9 using the NCI serum bank. Int J Cancer 1984;33:339-45.
3. Steinberg W. The clinical utility of the CA19-9 tumor associated antigen. Am J Gastroenterol 1990;85:350-5.
4. Ritts RE, Pitt HA. CA19-9 in pancreatic cancer. Surg Oncol Clin North Am 1998;7:93-101.
5. Koopman J, Zhang Z, White N, et al. SELDI approach for biomarker identification in the diagnosis of pancreatic adenocarcinoma. Proc Am Assoc Cancer Res 2003;44:1143.
6. Chen G, Yu Y, Chen S, Zhang W, Xu, Y. Serum fingerprinting as novel biomarkers for detecting pancreatic cancer. Proc Am Assoc Cancer Res 2003;44:1361.
7. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
8. Liotta LA, Petricoin EF, Ardenkani AM, et al. General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol Oncol 2003;88:S25-8.
9. Lawrie LC, Curran S, McLeod HL, Fothergill JE, Murray GI. Application of laser capture microdissection and proteomics in colon cancer. Mol Pathol 2001;54:253-8.
10. Adam B-L, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. 2002;62:3609-14.
11. Dwek MV, Alaiya AA. Proteome analysis enables separate clustering of normal breast, benign breast and breast cancer tissues. Br J Cancer 2003;89:305-7.
12. Bluemke DA, Cameron JL, Hruban RH, et al. potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathological correlation. Radiology 1995;197:381-5.
13. Irie H, Honda H, Kaneko K, Kuroiwa T, Yoshimitsu K, Masuda K. Comparison of helical CT and MR imaging in detecting and staging small pancreatic adenocarcinoma. Abdom Imaging 1997;22:429-33.
14. Hough TJ, Raptopoulos V, Siewert B, Matthews JB. Teardrop superior mesenteric vein: CT sign for unresectable carcinoma of the pancreas. AJR Am J Roentgenol 1999;173:1509-12.
15. Bennett GL, Hann LE. Pancreatic ultrasonography. Surg Clin North Am 2001;81:259-81.
16. Bottger TC, Boddin J, Duber C, Heintz A, Kuchle R, Junginger T. Diagnosing and staging of pancreatic carcinoma - what is necessary? Oncology 1998;55:122-9.
17. Ariyama J, Suyama M, Satoh K, Wakabayashi K. Endoscopic ultrasound and intraductal ultrasound in the diagnosis of small pancreatic tumors. Abdom Imaging 1998;23:380-6.
18. Fayad LM, Mithcell DG. Magnetic resonance imaging of pancreatic adenocarcinoma. Int J Gastroent Cancer 2001;30:19-25.
19. Ly JN, Miller FH. MR imaging of the pancreas: a practical approach. Radiol Clin North Am 2002;40:1289-306.
20. Talamonti MS, Denham W. Staging and surgical management of pancreatic and biliary cancer and inflammation. Radiol Clin North Am 2002;40:1397-410.
21. Freeny PC. Pancreatic carcinoma: imaging update 2001. Dig Dis 2001;19:37-46.
22. 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. Gut 2003;4 (suppl):23-9.
23. Sohn SK, Ahn BC, Lee SW, et al. Bone marrow immunoscintigraphy using technetium-99m anti-granulocyte antibody in multiple myeloma. Eur J Nucl Med Mol Imaging 2002;29:591-6.
24. Krause T, Eisenmann N, Reinhardt M, et al. Bone marrow scintigraphy using technetium-99m antigranulocyte antibody in malignant lymphomas. Ann Oncol 1999;10:79-85.
25. Behr TM, Holler E, Gratz S, et al. CD22 is a suitable target molecule for detection and high-dose, myeloablative radioimmunotherapy with the monoclonal antibody LL2 in acute lymphatic leukemia and Waldenström's macroglobulinaemia. Tumor Targeting 1998;3:32-40.
26. Gasparini M, Bombardieri E, Tondini C, et al. Clinical utility of radioimmunoscintigraphy of non-Hodgkin's lymphoma with radiolabeled LL2 monoclonal antibody, LymphoSCAN: preliminary results. Tumori 1995;81:173-8.
27. Hladik P, Vizda J, Bedrna J, et al. Immunoscintigraphy and intra-operative radioimmunodetection in the treatment of colorectal carcinoma. Colorectal Dis 2001;3:380-6.
28. Lechner P, Lind P, Goldenberg DM. CEA immunoscintigraphy detects resectable rectal cancer recurrence and improves survival. Coloproctology 2000;22:23-8.
29. Lechner P, Lind P, Goldenberg DM. Can postoperative surveillance with serial CEA immunoscintigraphy detect resectable rectal cancer recurrence and potentially improve tumor-free survival? J Am Coll Surg 2000;191:511-8.
30. Juweid M, Sharkey RM, Behr TM, et al. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol 1996;14:1209-17.
31. Juweid M, Sharkey RM, Swayne LC, Goldenberg DM. Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies. Surgery 1997;122:1156-65.
32. 99mTc-BDI-1 in the diagnosis of bladder cancer. Chin Med J (Engl) 2000;113:396-9.
33. Kalofonos HP, Karamouzis MV, Epenetos AA. Radioimmunoscintigraphy in patients with ovarian cancer. Acta Oncol 2001;40:549-57.
34. Kalofonos HP, Giannakenas C, Kosmas C, et al. Radioimmunoscintigraphy in patients with ovarian cancer. Acta Oncol 1999;38:629-34.
35. Manyak MJ, Hinkle GH, Olsen JO, et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 1999;54:1058-63.
36. Goldenberg DM, Nabi HA, Sullivan CL, et al. Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast cancer. Cancer 2000;89:104-15.
37. Chang, C-H, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther 2002;1:553-63.
38. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003;63:354-63.
39. Vuillez J Ph, Moro D, Brichon PY, et al. Two-step immunoscintigraphy for non-small cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 1997;38:507-11.
40. Le Doussal J-M, Chetanneau A, Gruaz-Guyon A, et al. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: Pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med 1993;34:1662-71.
41. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987;28:1294-302.
42. Karacay H, Sharkey RM, Govindan SV, et al. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer Reagent development. Bioconj Chem 1997;8:585-94.
43. Sharkey RM, Karacay H, Griffiths GL, et al. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconj Chem 1997;8:595-604.
44. Peltier P, Curtet C, Chatal J-F, et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA bispecific antibody and an indium-111-labeled dimer. J Nucl Med 1993;34:1267-73.
45. Barbet J, Peltier P, Bardet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med 1998;39:1172-8.
46. Kim YS, Gum J Jr., Brockhausen I. Mucin glycoproteins in neoplasia Glycoconj J 1996;13:693-707.
47. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001;6:339-53.
48. Taylor-Papadimitriou J, Burchell JM, Plunkett T, et al. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002;7:209-21.
49. Ringel J, Lohr M. The MUC gene family: Their role in diagnosis and early detection of pancreatic cancer. Mol Cancer 2003;2:9.
50. Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer 1994;57:204-10.
51. Gold DV, Alisauskas R, Sharkey RM. Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4. Cancer Res 1995;55:1105-10.
52. Cardillo TM, Ying Z, Gold DV. Therapeutic advantage of (90) yttrium-versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res 2001;7:3186-92.
53. Gold DV, Schutsky K, Modrak D, Cardillo TM. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res 2003;9:3929S-37S.
54. Berry N, Jones DB, Smallwood J, Taylor I, Kirkham N, Taylor-Papadimitriou J. The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer. Br J Cancer 1985;51:179-86.
55. Granowska M, Mather SJ, Jobling T, et al. Radiolabelled stripped mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian tumours. Int J Biol Markers 1990;5:89-96.
56. Peterson JA, Zava DT, Duwe AK, Blank EW, Battifora H, Ceriani RL. Biochemical and histological characterization of antigens preferentially expressed on the surface and cytoplasm of breast carcinoma cells identified by monoclonal antibodies against the human milk fat globule. Hybridoma 1990;9:221-35.
57. Hollingsworth MA, Strawhecker JM, Caffrey TC, Mack DR. Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines. Int J Cancer 1994;57:198-203.
58. Andrianifahanana M, Moniaux N, Schmied BM, et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 2001;7:4033-40.
59. Mariani G, Molea N, Bacciardi D, et al. Initial targeting, biodistribution and pharmacokinetics screening of the monoclonal antibody PAM 4 for immunoscintigraphy in patients with pancreatic cancer. Cancer Res 1995;55:5911s-5s.
60. Gold DV, Cardillo T, Goldenberg DM, Sharkey RM. Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Crit Rev Hematol/Oncolo 2001;39:147-54.
61. Karacay H, McBride WJ, Griffiths GL, et al. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a Tc-99m/Re-188 labeled peptide. Bioconj Chem 2000;11:842-54.
62. Govindan SV, Shih LB, Goldenberg DM, et al. 90-Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies. Bioconjug Chem 1998;9:773-82.
63. Cummins DH, Rutter EW Jr, Fordyce WA. A convenient synthesis of bifunctional chelating agents based on diethylenetriaminepentaacetic acid and their coordination chemistry. Bioconj Chem 1991;2:180-6.
64. McConahey PJ, Dixon FJ. A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol 1966;29:185-9.
65. Karacay H, Sharkey RM, McBride WJ, et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: Role of the bispecific antibody's valency for the tumor target antigen. Bioconj Chem 2002;13:1054-70.
66. Hajjar G, Sharkey RM, Burton J, et al. Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer 2002;2:31-42.
67. LaValle GJ, Martinez DA, Sobel D, DeYoung B, Martin EW Jr. Assessment of disseminated pancreatic cancer: a comparison of traditional exploratory laparotomy and radioimmunoguided surgery. Surgery 1997;122:867-71.
68. Kaufmann LW, Vaillant JC, van Gulik TM, van Royen EA, Parc R, Obertop H. Efficacy of monoclonal antibody 131I-B72.3 immunoscintigraphy of pancreatic adenocarcinoma xenografts in nude mice. Eur J Surg 1999;165:659-64.
69. Goldrosen MH, Loftus R, Lloyd F, et al. Localization of monoclonal antibody in a novel nude mouse model of pancreatic cancer. Proc Am Assoc Cancer Res 1988;29:419.
70. Klapdor R, Montz R, Greten H, et al. Immunszintigraphie und Radioimmuntherapie des transpantierten Pankreaskarzinoms. Nucl Med 1985;124:227-31.
71. 2 fragments of monoclonal antibodies to CA19-9 and CEA. In: C. Winkler, editor. Nuclear Medicine in Clinical Oncology: Current Status and Future Aspects, New York: Springer Verlag, 1986. p. 391-6.
72. Nakamura K, Kubo A, Hashimoto S, Furuchi T, Takami H, Abe O. Radioimmunodetection of human pancreatic tumor xenografts using Du-Pan 2 monoclonal antibody. Ann Nucl Med 1988;2:1-6.
73. Klapdor R, Bahlo M, Montz R, Dietal M, Arps H, Bosslet K. Experimental and clinical studies with the new monoclonal antibody 494/32 in pancreatic carcinomas. Digestion 1986;35:31.
74. Kairemo KJA. Radioimmunotherapy of solid cancers. Acta Oncologica 1996;35:343-55.
75. Sharkey RM, Blumenthal RD, Hansen HJ, Goldenberg DM. Biological considerations for radioimmunotherapy. Cancer Res 1990;50:964s-9s.
76. Milenic DE, Yokota T, Filipula DR, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363-71.
77. Zhu H, Baxter LT, Jain RK. Potential and limitation of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. J Nucl Med 1997;38:731-41.
78. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201-12.
79. Rolleman EJ, Valkema R, De Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabeled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9-15.
80. Boerman OC, Kranenborg MHGC, Oosterwijk E, et al. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res 1999;59:4400-5.
81. Le Doussal J-M, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, Barbet J. Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res 1990;50:3445-52.
82. 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol 2001;19:53-8.
83. Schuhmacher J, Klivenyi G, Kaul S, et al. Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET. Nucl Med Biol 2001;28:821-8.
84. Schuhmacher J, Kaul S, Klivenyi G, et al. Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res 2001;61:3712-7.